Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

One abstract reviewed results from Part A and Part C. 1 Part A was a 24-week study comparing dupilumab 300 mg vs placebo and Part C was a 28-week extended active treatment period for patients who ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Meeting Coverage > ACG Dupilumab Helped Kids With Eosinophilic Esophagitis Achieve Needed Weight Gain — The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil ...

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody ...

The dupilumab group also saw an improvement in their hives symptoms, with an 8.5-point greater decrease versus the placebo group in their Urticaria Activity Score over 7 days (UAS7) for a mean ...

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase ...

Dupilumab-Associated Ocular Surface Disease in Patients With AD: Unravelling the Link Kate Johnson October 21, 2022 0 ...

“Unlike other trials of biologics for COPD, dupilumab also resulted in a significant improvement in lung function and symptoms within 2 weeks of initiation, likely due to suppression of mucus ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...